The FDA has given another approval to Novartis for chimeric antigen receptor (CAR) T-cell therapy KYMRIAH, a personalized cell therapy product, the development of which was originated at University of Pennsylvania. Originally approved for children and young adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, it is now also indicated for adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.
Product page: KYMRIAH…